Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.
[BACKGROUND] The gut microbiome has emerged as a critical modulator of cancer immunotherapy response.
APA
Liu K, Xue X, et al. (2026). Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.. Oncology research, 34(2), 23. https://doi.org/10.32604/or.2025.072661
MLA
Liu K, et al.. "Gut Associated Metabolites Enhance PD-L1 Blockade Efficacy in Prostate Cancer.." Oncology research, vol. 34, no. 2, 2026, pp. 23.
PMID
41613795
Abstract
[BACKGROUND] The gut microbiome has emerged as a critical modulator of cancer immunotherapy response. However, the mechanisms by which gut-associated metabolites influence checkpoint blockade efficacy in prostate cancer (PC) remain not fully explored. The study aimed to explore how gut metabolites regulate death-ligand 1 (PD-L1) blockade via exosomes and boost immune checkpoint inhibitors (ICIs) in PC.
[METHODS] We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines and transgenic adenocarcinoma of the mouse prostate (TRAMP) models.
[RESULTS] We identified two metabolites, 16(R)-Hydroxyeicosatetraenoic acid (16(R)-HETE) and 6-Keto-Prostaglandin E1 (6-Keto-PGE1), that positively correlated with the plasma exosomal PD-L1 levels. The experiments found that both 16(R)-HETE and 6-Keto-PGE1 can enhance PD-L1 expression at the mRNA, protein, and exosome levels in both human and mouse PC cell lines, which were also validated based on subcutaneous mouse models. Both metabolites significantly promoted the anti-PD-L1 efficacy against PC on a TRAMP mouse model.
[CONCLUSIONS] Targeting the "gut-tumor metabolic axis" is a promising strategy to improve the efficacy of immune checkpoint inhibitors in tumors.
[METHODS] We recruited 70 PC patients to set up into five subgroups. The integrated multi-omics analysis was performed. In parallel, we validated the function of gut microbiome-associated metabolites on PD-L1 production and immunotherapy treatment efficacy in PC cell lines and transgenic adenocarcinoma of the mouse prostate (TRAMP) models.
[RESULTS] We identified two metabolites, 16(R)-Hydroxyeicosatetraenoic acid (16(R)-HETE) and 6-Keto-Prostaglandin E1 (6-Keto-PGE1), that positively correlated with the plasma exosomal PD-L1 levels. The experiments found that both 16(R)-HETE and 6-Keto-PGE1 can enhance PD-L1 expression at the mRNA, protein, and exosome levels in both human and mouse PC cell lines, which were also validated based on subcutaneous mouse models. Both metabolites significantly promoted the anti-PD-L1 efficacy against PC on a TRAMP mouse model.
[CONCLUSIONS] Targeting the "gut-tumor metabolic axis" is a promising strategy to improve the efficacy of immune checkpoint inhibitors in tumors.
MeSH Terms
Male; Humans; Animals; Prostatic Neoplasms; B7-H1 Antigen; Mice; Immune Checkpoint Inhibitors; Gastrointestinal Microbiome; Cell Line, Tumor; Exosomes; Mice, Transgenic; Disease Models, Animal
같은 제1저자의 인용 많은 논문 (5)
- Can full-volume dual-energy CT quantitative parameter nomogram predict the new IASLC grade of pure solid invasive pulmonary adenocarcinoma.
- Sex Disparities in Breast Cancer Survival According to Clinical Treatment Score Post-5 Years (CTS5) Risk Stratification.
- Discovery and development of the preclinical candidate (SH-1092), a potent third generation EGFR inhibitor for the treatment of NSCLC.
- Taurine suppresses gastric intestinal metaplasia in patient-derived organoids and mice.
- Breast cancer susceptibility gene 2 upregulation alleviated cardiac hypertrophy in angiotensin II-treated mice.